Myriad Genetics Expands Collaboration with AstraZeneca on Olaparib Phase 3 Clinical Trials

Myriad Genetics Expands Collaboration with AstraZeneca on Olaparib Phase 3
Clinical Trials

SALT LAKE CITY, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.
(Nasdaq:MYGN) announced today that it has entered into an expanded,
nonexclusive global collaboration agreement with AstraZeneca to provide
companion diagnostics for the olaparib Phase 3 clinical development program.
Olaparib is an investigational orally active poly-ADP ribose polymerase (PARP)
inhibitor being developed by AstraZeneca for the treatment of various tumor
types including BRCA-mutated breast and ovarian cancers.

Under the expanded agreement, Myriad will build out a new laboratory within
its Salt Lake City facility in accordance with U.S. Food and Drug
Administration (FDA) regulations for companion diagnostic devices. In August,
the FDA approved the Investigational Device Exemption (IDE) for BRACAnalysis^®
filed by Myriad, enabling clinical studies with olaparib to include
BRACAnalysis testing as a companion diagnostic.

"We are excited to be expanding our companion diagnostic collaboration with
AstraZeneca," said Peter D. Meldrum, president and CEO of Myriad. "We are
working together to transform the future of personalized medicine and to
deliver significant value for patients and the healthcare system, and we are
committed to being a leader in companion diagnostics."

The collaboration builds on an existing agreement through which Myriad
provided supply of BRACAnalysis to support the Phase 2 development program for
olaparib in breast and ovarian cancers.Specific terms were not disclosed.

"Our hope is that the Phase 3 development program for olaparib will result in
a new treatment option for patients suffering from BRCA-mutated ovarian and
breast cancers, accompanied by a diagnostic to help physicians identify the
patients for whom the therapy might be most appropriate," said Ruth March,
vice president and head of Personalised Healthcare and Biomarkers at
AstraZeneca."Myriad is well positioned to provide high quality BRCA mutation
testing services and the infrastructure to offer testing to support therapy
choices."

Olaparib is a novel investigational PARP inhibitor that induces synthetic
lethality in homozygous BRCA-deficient cells.Phase II clinical data presented
at ASCO 2013 demonstrated that patients with BRCA mutated ovarian cancers
received the most clinical benefit from maintenance treatment with
olaparib.BRACAnalysis is the gold standard diagnostic test to confirm the
presence of aBRCAgene mutation.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making
a difference in patients' lives through the discovery and commercialization of
transformative tests to assess a person's risk of developing disease, guide
treatment decisions and assess risk of disease progression and recurrence.
Myriad's portfolio of molecular diagnostic tests are based on an understanding
of the role genes play in human disease and were developed with a commitment
to improving an individual's decision making process for monitoring and
treating disease. Myriad is focused on strategic directives to introduce new
products, including companion diagnostics, as well as expanding
internationally. For more information on how Myriad is making a difference,
please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo and BRACAnalysis are trademarks or registered
trademarks of Myriad Genetics, Inc. in the United States and other countries.
MYGN-F, MYGN-G

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the success, completion and regulatory approval of the expanded
collaboration with AstraZeneca to provide BRACAnalysis testing as a companion
diagnostics for the olaparib Phase 3 clinical development program; the build
out of a new laboratory within the Company's Salt Lake City facility in
accordance with U.S. Food and Drug Administration (FDA) regulations for
companion diagnostic devices to supply BRACAnalysis testing; and the Company's
strategic directives under the caption "About Myriad Genetics".These
"forward-looking statements" are management's present expectations of future
events and are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those described in the
forward-looking statements.These risks include, but are not limited to: the
risk that sales and profit margins of our existing molecular diagnostic tests
and companion diagnostic services may decline or will not continue to increase
at historical rates; risks related to changes in the governmental or private
insurers reimbursement levels for our tests; the risk that we may be unable to
develop or achieve commercial success for additional molecular diagnostic
tests and companion diagnostic services in a timely manner, or at all; the
risk that we may not successfully develop new markets for our molecular
diagnostic tests and companion diagnostic services, including our ability to
successfully generate revenue outside the United States; the risk that
licenses to the technology underlying our molecular diagnostic tests and
companion diagnostic services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays or other
problems with operating our laboratory testing facilities; risks related to
public concern over our genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the United States
and foreign countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain new
corporate collaborations or licenses and acquire new technologies or
businesses on satisfactory terms, if at all; risks related to our ability to
successfully integrate and derive benefits from any technologies or businesses
that we license or acquire; risks related to increased competition and the
development of new competing tests and services; the risk that we or our
licensors may be unable to protect or that third parties will infringe the
proprietary technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents; risks related to changes
in intellectual property laws covering our molecular diagnostic tests and
companion diagnostic services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et al; risks of
new, changing and competitive technologies and regulations in the United
States and internationally; and other factors discussed under the heading
"Risk Factors" contained in Item 1A of our most recent Annual Report on Form
10-K filed with the Securities and Exchange Commission, as well as any updates
to those risk factors filed from time to time in our Quarterly Reports on Form
10-Q or Current Reports on Form 8-K. All information in this press release is
as of the date of the release, and Myriad undertakes no duty to update this
information unless required by law.

CONTACT: Media Contact:
         Ron Rogers
         (801) 584-3065
         rrogers@myriad.com
        
         Investor Contact:
         Scott Gleason
         (801) 584-1143
         sgleason@myriad.com